LDS/Medical Tests/Catechol-O-methyltransferase Genotyping (COMT)

Catechol-O-methyltransferase Genotyping (COMT)

Catechol O-methyltransferase (COMT) catalyzes and degrades catecholamine neurotransmitters such as dopamine, adrenaline and noradrenaline, catechol-estrogens and related compounds and is encoded by the COMT gene located on the long arm of chromosome 22. Alternative promoters in the COMT gene result in two different forms of the COMT protein: a soluble short form expressed by liver and kidney; and a membrane-bound long form expressed by neurons in the brain.

The role of COMT in maintaining the levels of neurotransmitter dopamine in the prefrontal cortex of the brain has been extensively studied because it is implicated in the response to antipsychotic drugs in persons with schizophrenia. More than twenty single nucleotide polymorphisms (SNPs) involving the COMT gene have been described in the literature; however, the most clinically relevant SNP involves a G>A base pair change at position 472 (G472A). This missense mutation leads to amino acid change from valine to methionine in the codon 158 (Val158Met) in the membrane-bound form and valine to methionine in the codon 108 (Val108Met) in the soluble form. Collectively, this mutation is designated as Val108/158Met. This amino acid change leads to reduced activity of the enzyme COMT, predominantly in the prefrontal cortex of the brain.

In schizophrenia, a heterogeneous psychiatric disorder characterized by one or more symptoms including delusions, hallucinations, apathy, social withdrawal, and cognitive defects, some studies report that patients carrying the low-activity Met allele of COMT Val158Met (heterozygous or homozygous) show improved cognitive performance following antipsychotic treatment compared with Val/Val homozygotes; however, findings are inconsistent across studies, and the underlying pharmacodynamics is not completely understood.

The COMT gene is also widely studied in the context of pathogenesis of breast cancer. The functional polymorphism Val158Met is hypothesized to be a risk factor, given that the reduced activity of COMT leads to reduced degradation of catechol-estrogens, the hormones that drive proliferation of ductal epithelial cells in the breast tissue. However, large multicenter studies and meta-analyses have failed to identify COMT Val158Met as an independent risk factor for breast cancer. This remains an area of clinical and research interest.

  • To identify patients with schizophrenia who may show cognitive improvement following antipsychotic therapy
  • Determining therapeutic strategy for drugs metabolized by COMT
  • Patients with schizophrenia who carry the low-activity Met allele of COMT Val158Met (heterozygous or homozygous) may show cognitive improvement following antipsychotic therapy, although findings across studies are inconsistent.
  • Presence of COMT Val158Met doesn't guarantee a positive response to antipsychotic therapy since the activity of COMT could be affected by other drugs.
  • Mutations in the primer binding sites may lead to false negative and/or invalid results.
  • This test will not detect polymorphisms other than Val158Met in the COMT gene that might alter the function of COMT. Absence of Val158Met does not rule out the possibility of a reduced COMT function.
  • This test may not be used to predict the risk of development of schizophrenia and/or breast cancer in any specific population since the etiology for these entities is multifactorial.

Negative for mutations analyzed, (COMT Val108/158Met not detected).

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood (EDTA), buccal swab, saliva.

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days

Catecholamine levels, Serotonin, vanillylmandelic acid, Pheochromocytoma Screen

3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login